PT  - JOURNAL ARTICLE
AU  - Song, No-Joon
AU  - Allen, Carter
AU  - Vilgelm, Anna E.
AU  - Riesenberg, Brian P.
AU  - Weller, Kevin P.
AU  - Reynolds, Kelsi
AU  - Chakravarthy, Karthik B.
AU  - Kumar, Amrendra
AU  - Khatiwada, Aastha
AU  - Sun, Zequn
AU  - Ma, Anjun
AU  - Chang, Yuzhou
AU  - Yusuf, Mohamed
AU  - Li, Anqi
AU  - Zeng, Cong
AU  - Evans, John P.
AU  - Bucci, Donna
AU  - Gunasena, Manuja
AU  - Xu, Menglin
AU  - Liyanage, Namal P.M.
AU  - Bolyard, Chelsea
AU  - Velegraki, Maria
AU  - Liu, Shan-Lu
AU  - Ma, Qin
AU  - Devenport, Martin
AU  - Liu, Yang
AU  - Zheng, Pan
AU  - Malvestutto, Carlos D.
AU  - Chung, Dongjun
AU  - Li, Zihai
TI  - Treatment with Soluble CD24 Attenuates COVID-19-Associated Systemic Immunopathology
AID  - 10.1101/2021.08.18.21262258
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.18.21262258
4099  - http://medrxiv.org/content/early/2021/09/16/2021.08.18.21262258.short
4100  - http://medrxiv.org/content/early/2021/09/16/2021.08.18.21262258.full
AB  - BACKGROUND SARS-CoV-2 causes COVID-19 through direct lysis of infected lung epithelial cells, which releases damage-associated molecular patterns (DAMPs) and induces a pro-inflammatory cytokine milieu causing systemic inflammation. Anti-viral and anti-inflammatory agents have shown limited therapeutic efficacy. Soluble CD24 (CD24Fc) is able to blunt the broad inflammatory response induced by DAMPs in multiple models. A recent randomized phase III trial evaluating the impact of CD24Fc in patients with severe COVID-19 demonstrated encouraging clinical efficacy.METHODS We studied peripheral blood samples obtained from patients enrolled at a single institution in the SAC-COVID trial (NCT04317040) collected before and after treatment with CD24Fc or placebo. We performed high dimensional spectral flow cytometry analysis of peripheral blood mononuclear cells and measured the levels of a broad array of cytokines and chemokines. A systems analytical approach was used to discern the impact of CD24Fc treatment on immune homeostasis in patients with COVID-19.FINDINGS Twenty-two patients were enrolled, and the clinical characteristics from the CD24Fc vs. placebo groups were matched. Using high-content spectral flow cytometry and network-level analysis, we found systemic hyper-activation of multiple cellular compartments in the placebo group, including CD8+ T cells, CD4+ T cells, and CD56+ NK cells. By contrast, CD24Fc-treated patients demonstrated blunted systemic inflammation, with a return to homeostasis in both NK and T cells within days without compromising the ability of patients to mount an effective anti-Spike protein antibody response. A single dose of CD24Fc significantly attenuated induction of the systemic cytokine response, including expression of IL-10 and IL-15, and diminished the coexpression and network connectivity among extensive circulating inflammatory cytokines, the parameters associated with COVID-19 disease severity.INTERPRETATION Our data demonstrates that CD24Fc treatment rapidly down-modulates systemic inflammation and restores immune homeostasis in SARS-CoV-2-infected individuals, supporting further development of CD24Fc as a novel therapeutic against severe COVID-19.FUNDING NIHCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by National Institutes of Health (NIH) grants, including R01AI077283, R01CA213290 to Z.L; and R37CA233770 to A.E.V. Z.L is also supposed by funding from the Pelotonia Foundation. Research reported in this publication was also supported by The Ohio State University Comprehensive Cancer Center and the NIH under grant number P30 CA016058.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study included samples from patients enrolled in NCT04317040 at The Ohio State University Wexner Medical Center. Trial and protocol were approved by Western Institutional Review Board. The study was monitored by a contract research organization; safety reports were submitted to an independent Data and Safety Monitoring Board. This trial was conducted in compliance with protocol, International Conference on Harmonization Good Clinical Practice, and all applicable regulatory requirements.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials. Raw data that support the findings of this study are available on request from the corresponding author, Dr. Zihai Li